Dose-volume histogram parameters and clinical factors associated with pleural effusion after chemoradiotherapy in esophageal cancer patients.

[1]  Makiko Tanaka,et al.  Results of radiotherapy for inoperable locally advanced esophageal cancer. , 1989, International journal of radiation oncology, biology, physics.

[2]  S. Coons,et al.  Histopathology of astrocytomas: Grading, patterns of spread, and correlation with modern imaging modalities , 1991 .

[3]  K. Eguchi,et al.  Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion. , 1991, Cancer research.

[4]  G. Fraile,et al.  Recurrent massive pleural effusion as a late complication of radiotherapy in Hodgkin's disease. , 1991, Chest.

[5]  J. Cooper,et al.  Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. , 1992, The New England journal of medicine.

[6]  N. Morrone,et al.  Bilateral pleural effusion due to mediastinal fibrosis induced by radiotherapy. , 1993, Chest.

[7]  S. Yoshida,et al.  Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Cooper,et al.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. , 1999, JAMA.

[9]  J A Purdy,et al.  Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC) , 1999, International journal of radiation oncology, biology, physics.

[10]  H. Kataoka,et al.  Pericardial and pleural effusions in decompensated chronic heart failure. , 2000, American heart journal.

[11]  Y. Kitagawa,et al.  Improvement in the Results of Surgical Treatment of Advanced Squamous Esophageal Carcinoma During 15 Consecutive Years , 2000, Annals of surgery.

[12]  R. Light,et al.  Clinical practice. Pleural effusion. , 2002, The New England journal of medicine.

[13]  S. Yoshida,et al.  Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. , 2003, International journal of radiation oncology, biology, physics.

[14]  Narikazu Boku,et al.  Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  T. Crosby,et al.  The significance of cardiac doses received during chemoradiation of oesophageal and gastro-oesophageal junctional cancers. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[16]  D. Kwong,et al.  Inverse planning in three-dimensional conformal and intensity-modulated radiotherapy of mid-thoracic oesophageal cancer , 2004 .

[17]  Henk-Jan Guchelaar,et al.  Cardiotoxicity of cytotoxic drugs. , 2004, Cancer treatment reviews.

[18]  K. Jingu,et al.  Results of radiation therapy combined with nedaplatin (cis-diammine-glycoplatinum) and 5-Fluorouracil for postoperative locoregional recurrent esophageal cancer , 2006, BMC Cancer.

[19]  H. Fukuda,et al.  The utility of 18F-fluorodeoxyglucose positron emission tomography for early diagnosis of radiation-induced myocardial damage. , 2006, International journal of radiation oncology, biology, physics.

[20]  George D Wilson,et al.  Biologic basis for combining drugs with radiation. , 2006, Seminars in radiation oncology.

[21]  M. Koukourakis,et al.  Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. , 2006, International journal of radiation oncology, biology, physics.

[22]  R. Mohan,et al.  Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. , 2006, International journal of radiation oncology, biology, physics.

[23]  K. Kaneko,et al.  Late toxicity in complete response cases after definitive chemoradiotherapy for esophageal squamous cell carcinoma , 2006, Journal of Gastroenterology.

[24]  H. Fukuda,et al.  Temporal change in brain natriuretic Peptide after radiotherapy for thoracic esophageal cancer. , 2007, International journal of radiation oncology, biology, physics.

[25]  Charles S Mayo,et al.  Hybrid IMRT for treatment of cancers of the lung and esophagus. , 2008, International journal of radiation oncology, biology, physics.

[26]  R. Mohan,et al.  Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy. , 2008, International journal of radiation oncology, biology, physics.

[27]  Hisao Ito,et al.  Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[28]  Yoshiyuki Suzuki,et al.  Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. , 2010, International journal of radiation oncology, biology, physics.